Every physician is treating a rare disease patient

- even if they don’t know it.

Over 300 million patients are affected worldwide and 1 in 12 Canadians has a rare disorder. Many others are affected or at risk but remain undiagnosed and unaware. With over 7000 rare diseases identified and medications getting more specialized and personalized, primary care physicians are increasingly challenged to keep up and get their patients properly diagnosed, referred to the right specialty, and on the right care pathway.
The result? Patients with rare conditions are being bounced around the system, experiencing poor quality of life and early deaths.
Traditional investments in technology have done little to help over-worked and over-burdened primary care physicians diagnose complex patients.
Khure Health makes it easier for physicians to identify and treat rare and specialty conditions.

Comprehensive, integrated clinical dashboard.

Integrating guidance from centres of excellence, key opinion leaders and health associations, Khure Health’s platform enables physicians to assess thousands of their own patients within minutes.

Identify target patients using global clinical research and deep analytics.​

Match high-risk patients with the right care pathway.

Support the patient-provider journey to ensure optimal treatment.

Platform powered by advanced technology.

The Khure Health Platform leverages

Advanced logic and decisioning based on clinical guidelines and leading peer reviewed research.

Natural Language Processing (NLP) and unstructured data techniques.

Machine-Learning and population health analytics.

We put clinical dashboards and tools right in the physician’s hand to quickly identify complex patients who:

  • Are undiagnosed and could benefit from improved care pathways
  • Are eligible for enrolment in active clinical trials 

The results speak for themselves

Khure Health enables primary care physicians to diagnose rare and specialty conditions faster and more efficiently. 

Oncology Cardiology Dermatology Respiratory Musculoskeletal Orphan indications

Multiple rare and specialty diseases supported.

0 s
of patient screens performed on the Khure Health platform
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Every day, new patients are identified and placed on optimal care pathways

Program Spotlight

Example clinical programs Khure Health is supporting to identify undertreated patients and put them on the right care pathway
Myelofibrosis is estimated to affect 1 in 100,000 people, with the majority of patients diagnosed over the age of 50. Myelofibrosis is a type of bone marrow cancer that affects the body’s ability to produce blood cells. In normal bone marrow, cells called fibroblasts produce the fibrous tissue that supports blood-producing cells. In myelofibrosis, the fibroblasts make too much fibrous tissue, causing scarring to the bone marrow which reduced the body’s ability to make enough blood cells. Often, myelofibrosis comes on slowly and manifests itself as weight-loss, tiredness, fatigue, fever and generalized weakness. This subsequently leads to a delay in diagnosis and poor health outcomes. With treatment, patients can relieve complications and delay progression of the disease. Khure Health helps with early diagnosis to ensure patients receive the best treatment possible.

Gaucher disease affects 1 in 100,000 people. It is a rare, inherited lysosomal storage disorder characterized by the build-up of beta-glucocerebroside. There are three main types of Gaucher disease, with Type 1 being the most common form that occurs at any age.

Many people with Type 1 can be asymptomatic or show mild symptoms due to the absence of impact on the nervous system. This can delay their path to diagnosis and treatment. Without proactive treatment, patients with Gaucher disease risk irreversible tissue and organ damage. With the right treatment, patients can prevent or improve their symptoms. Khure Health helps identify high risk patients who may benefit from further evaluation and treatment that can greatly improve their quality of life.

Severe asthma affects approximately 5% of the asthmatic population, with many experiencing significant healthcare issues and potentially requiring hospitalization. Uncontrolled asthma symptoms contribute to significant healthcare cost and burden. Novel care pathways and treatments have been identified that can greatly improve the patient’s quality of life and reduce their dependence on other therapies. Khure Health helps identify these under-diagnosed patients and ensure they are matched with the right care.

Loeys-Dietz syndrome (LDS) is an autosomal dominant genetic disorder that affects the connective tissues in the body. Patients with LDS present with multiple clinical manifestations that include craniofacial features, vascular findings, skeletal features, as well as cutaneous findings such as dystrophic scars and translucent skin.

LDS is a relatively rare condition impacting about 1 in 100,000 people. It has multiple subtypes as per the genes involved (TGFBR1, TGBFR2, TGFB2, TGFB3, SMAD3) with TGFBR1 (Type 1 LDS) and TGFBR2 (Type 2 LDS) being the most prevalent. The aggressiveness of vascular manifestations is a distinguishing factor when compared to other similar connective tissue disorders such as Marfan syndrome. This also makes it more severe than other disorders (average life expectancy of 37) and therefore, timely diagnosis is crucial.

Khure Health aids in early diagnosis and provides patients and physicians with the appropriate next steps for improving disease outcomes and quality of life.

Neuroblastoma is one of the most commonly occurring extracranial solid tumors in childhood. It is formed from neural crest cells in developing sympathetic systems. With a disease prevalence of 1-5/10,000, it is the most common malignancy in the first year of life.

While this disorder represents 5% of the total pediatric cancer diagnosis, it disproportionately results in 9% of the total pediatric deaths from cancer. The symptoms for this disorder can vary significantly as they depend on the size and the location of the tumor as well as the age of the patient. Metastases is present in about 50% of the patients during the diagnosis, with bone marrow, bone, and regional lymph nodes being the most common sites.

Recognizing high-risk patients early is key to help reduce mortality. Khure Health helps with early screening that can significantly improve survival rates and overall quality of life.